Though not heavily traded, things began to pick up for PSIDD (PositiveID Corporation) tremendously, after the company released a morning news announcement, this past Monday, in which they revealed that they launched the development of Firefly Dx. This news showed
Penny Stock Dream that the company is very actively moving forward with its internal operations and as a result of the update, saw a surge up 28.48% by the close. Although the stock only saw 244,044 trades for the day the news marked a move in the right direction for the company as it continues to see positive growth for its investors. At the rate at which the company has been shedding light on operations for interested investors, we believe that there may very well be a further volume spike as more begin to recognize what the company is currently working on. Even today, the company has released yet another major news release, announcing that their CEO has been interviewed on a segment on SmallCapVoice.com. The news release from this past Monday pertaining to the development of Firefly Dx, has greatly sparked the interest of
Penny Stock Dream and can be viewed in its entirety here:
"Photo Release -- PositiveID Corporation Launches Development of Firefly Dx to Confirm Biological Threats in the Field Within Mi"PositiveID Corporation ("PositiveID" or "Company") (OTCBBNULL), a developer of biological detection and diagnostics solutions, today announced it has launched the development of the Firefly Dx detection system ("Firefly"), a portable, hand-held, point-of-need molecular diagnostic system, which is being designed to provide test results from sample input through reporting of results in less than 15 to 30 minutes depending on the type of test performed. Firefly is expected to quickly process human and agricultural samples to provide accurate confirmation of biological threats via a smart-phone application.
[caption id="" align="alignnone" width="275"]
Firefly Dx is a portable, hand-held, point-of-need molecular diagnostic system.[/caption]
A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=18389
The goal of Firefly is to take the Company's patented molecular diagnostic technology underlying its M-BAND (Microfluidics-based Bioagent Networked Detector) airborne bio-threat detector and Dragonfly™ Rapid MDx Cartridge-based diagnostic system, and implement it in a handheld device that can be used anywhere, anytime to test for biological agents.
The Company believes the target markets for Firefly include military field deployments, remote areas with limited or no access to healthcare, border locations and others. The Company believes most of the competing technologies currently available for biological detection and diagnosis are costly, labor intensive, and often restricted to laboratory/clinical settings. This significantly limits effective point-of-care or timely monitoring of biological events at the point of need.
William J. Caragol, Chairman and CEO of PositiveID, stated, "The need for a hand-held system like Firefly is real. Whether natural or man-made, an invasive disease outbreak without proper monitoring or detection, which therefore results in less effective countermeasures, can seriously affect the health and commercial stability of livestock or human populations on a large scale. Recent events such as the ricin-laced letters sent to President Obama and other political leaders, as well as the emerging deadly strain of bird flu in China, underscore the necessity for a system like Firefly. We have begun conversations with several potential partners to attract the research and development capital to complete the development of this innovative system."
Firefly is being designed as a disposable, cartridge-based system to process a variety of sample types, including whole blood, buccal and nasopharyngeal swabs, urine, and environmental field samples. The incorporated, multiplex polymerase chain reaction ("PCR") assay is being designed to analyze for multiple, user-defined targets from a single sample. Furthermore, by taking advantage of the TaqMan®-based PCR assay and real-time detection, Firefly is being designed to measure altered gene expression levels such as those observed in endocrine diseases, radiation exposure, and cancer. Results can be immediately obtained and processed wherever you are via a smart-phone interface (or personal computer) with a specialized, mobile application and cloud-based data sharing and storage.
About PositiveID CorporationPositiveID Corporation is an emerging growth company and developer of biological detection systems for America's homeland defense industry as well as rapid medical testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including, without limitation, the likelihood that Firefly will be used in the identification of biological agents associated with weapons of mass destruction, point-of-need monitoring of pathogenic outbreaks and agricultural screening; the likelihood that Firefly is expected to quickly process human and agricultural samples to provide accurate confirmation of biological threats via a smart-phone application; the likelihood that target markets for Firefly include military field deployments, remote areas with limited or no access to healthcare, border locations and others; the likelihood that most of the competing technologies currently available for biological detection and diagnosis are costly, labor intensive, and often restricted to Laboratory/clinical settings; the likelihood that the need for Firefly is real; and all statements in this press release constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company's ability to target the bio-threat detection and rapid medical testing sectors; the Company's ability to attract the research and development capital to complete the development of Firefly; as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on April 16, 2013 under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law."This special release was clearly an exciting development for current investors, who are finally able to see the form of the product that they have been waiting to be released. While the Firefly Dx is not yet being sold, the image alone clearly gave investors a sense of the company moving in the right direction to get things done in a manner that may be beneficial to those that have been sticking with the company for whatever stretch of time they may have been.
Penny Stock Dream often looks for companies that are willing to go the extra mile to ensure that they actually put products into distribution. While being able to see a product image is a great thing, we still suggest that investors operate with caution because we have ourselves seen in the past, companies that release images and never actually put the real product out on the market. The most recent news article about the CEO's interview today, can be read in its entirety below:
"William J. Caragol, Chairman and CEO of PositiveID, is Featured in a New Audio Interview At SmallCapVoice.comAUSTIN, Texas, May 1, 2013 /PRNewswire/ -- SmallCapVoice.com, Inc. announced today that a new audio interview with PositiveID Corporation ("PositiveID" or "Company") (OTCBB: PSIDD), a developer of biological detection and diagnostics solutions, is now available. The interview can be heard at http://smallcapvoice.com/blog/4-30-13-smallcapvoice-interview-with-positiveid-corporation-psidd
William J. Caragol, Chairman and CEO of PositiveID, called into SmallCapVoice.com to discuss the recent milestones achieved by the Company, the launch of the development of the Firefly Dx detection system, the goals for PositiveID in 2013, and much more.
"We believe 2013 holds significant opportunity for PositiveID and we will continue our strategic focus on our biological detection and diagnostics capabilities," stated Caragol. "As we await the release of the final request for proposal from the Department of Homeland Security for Stage 1 of BioWatch Generation 3, expected to be released in 2013, we are also looking ahead to new applications of our patented technology such as our Firefly Dx detection system, a handheld, point-of-need system designed to be used in the identification of biological threats, including biological agents associated with bio-terrorism, within minutes."
While these sorts of interviews always seem to be very promising,
Penny Stock Dream always makes a note to keep from getting too excited. This is mainly because CEO's can say whatever they want in an interview but it is actual action and completion that makes the difference with these radio and talk shows. We will continue to watch PSIDD, to see what is to come from here on but have come to recognize that the majority of times that penny stock companies do these sorts of talk shows, the stock tends to dip lower, possibly because penny stock traders recognize that it is not the strongest sort of news that a company is able to report. If anything, they seem to be more along the lines of random fillers than anything else. Regardless of whether or not doing this radio address was the best choice for the company,
Penny Stock Dream continues to believe that there is a great deal of potential left in this company, so we suggest that all those following along with this report, continue to keep track of what is to come with PSIDD as we will ourselves.
While our general penny stock newsletter subscription services are absolutely free, many highly successful traders have opted to sign up to our elevated Platinum Membership services, for the purpose of receiving various special alerts in advance of free members. This has given them a significant advantage in their ability to digest key information before many others are able to. Those wishing to sign up to our special Platinum Membership package, can do so at
www.pennystockdream.com/platinum.
Pennystockdream.com and its employees are not registered as Investment Advisers in any jurisdiction whatsoever. We encourage all of those that are interested in trading penny stocks, or any other form of investment, to conduct their own research to garner a better understanding of what they are getting involved in. Be sure to read the full pennystockdream.com disclaimer at:
http://pennystockdream.com/disclaimer.